Treating hallucinations in Parkinson's disease.
Hallucinations
Lewy body disease
Parkinson’s disease
psychosis
treatment
Journal
Expert review of neurotherapeutics
ISSN: 1744-8360
Titre abrégé: Expert Rev Neurother
Pays: England
ID NLM: 101129944
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
pubmed:
14
11
2020
medline:
6
7
2022
entrez:
13
11
2020
Statut:
ppublish
Résumé
Hallucinations in Parkinson's disease are common, can complicate medication management and significantly impact upon the quality of life of patients and their carers. This review aims to examine current evidence for the management of hallucinations in Parkinson's disease. Treatment of hallucinations in Parkinson's disease should be both individualized and multifaceted. Screening, education, medication review and the avoidance of common triggers are important. For well-formed visual hallucinations, acetylcholinesterase inhibitors are recommended first-line. Refractory or severe symptoms may require the cautious use of atypical antipsychotics. Antidepressants may be beneficial in the appropriate setting. Unfortunately, current therapies for hallucinations offer only limited benefits and future research efforts are desperately required to improve the management of these challenging symptoms.
Identifiants
pubmed: 33183105
doi: 10.1080/14737175.2021.1851198
doi:
Substances chimiques
Antipsychotic Agents
0
Acetylcholinesterase
EC 3.1.1.7
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM